Surrogacy between event-free survival and overall survival in perioperative immunotherapy trials.
Abstract
623 Background: EFS/DFS are commonly used endpoints in perioperative immune checkpoint inhibitor (ICI) trials, but their reliability as surrogates for overall survival (OS) remains uncertain. For surrogacy to be established there should be strong and consistent correlation between the surrogate and definitive endpoints, and the surrogate endpoint should also predict the net effect of treatment on the clinical outcome. Methods: We conducted a trial-level analysis of neoadjuvant and perioperative phase III ICI trials (n=7), excluding adjuvant studies. Associations between log-transformed EFS/DFS hazard ratios (HRs) and log-transformed OS HRs were assessed using regression and Pearson R correlation with strong correlation was defined as R²≥0.70. Results: Only 6 trials (86%) had any OS data for analysis, no OS data have been reported for checkmate 77T. Pearson correlation between EFS and OS was 0.57 (0.04-0.99), R² value was 0.33. Conclusions: These findings suggest that EFS/DFS have suboptimal correlation with OS and therefore are unlikely to meet thresholds for surrogacy in perioperative ICI trials. Larger datasets with mature OS and individual patient data are required before surrogate endpoints can reliably guide clinical or regulatory decision-making. Surrogate validation summary. Trial EFS HR OS HR Checkmate 816 0.63 0.71 Keynote 671 0.58 0.72 AEGEAN 0.68 0.89 Checkmate 77T 0.58 NA Keynote 522 0.63 0.66 NIAGARA 0.68 0.75 MATTERHORN 0.71 0.78 EFS: Event-Free Survival; OS: Overall Survival; HR: Hazard Ratio.